Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1084759
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1084759
Cephalosporin Drugs Market, By Generation, By Type, By Formulation, By Indication, By Distribution Channel, and By Region - Size, Share, Trends, and Forecast, 2022 - 2028
PUBLISHED:
PAGES: 236 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization's (WHO) report of February 2021, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.
Market Dynamics
Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.
However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.
Key features of the study:
- This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cephalosporin drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Cephalosporin Drugs Market, By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- Global Cephalosporin Drugs Market, By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- Global Cephalosporin Drugs Market, By Formulation:
- Oral
- Tablets
- Capsules
- Liquid
- Injection
- Oral
- Global Cephalosporin Drugs Market, By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- Global Cephalosporin Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Cephalosporin Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation:
- Oral
- North America
- Tablets
- Capsules
- Liquid
- Injection
- By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation:
- Oral
- Injection
- Tablets
- Capsules
- Liquid
- Injection
- By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation:
- Oral
- Injection
- Tablets
- Capsules
- Liquid
- Injection
- By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation:
- Oral
- Injection
- Tablets
- Capsules
- Liquid
- Injection
- By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation:
- Oral
- Injection
- Tablets
- Capsules
- Liquid
- Injection
- By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Generation:
- First-generation Cephalosporin
- Second-generation Cephalosporin
- Third-generation Cephalosporin
- Fourth-generation Cephalosporin
- Fifth-generation Cephalosporin
- By Type:
- Branded Cephalosporin Drugs
- Generic Cephalosporin Drugs
- By Formulation:
- Oral
- Injection
- Tablets
- Capsules
- Liquid
- Injection
- By Indication:
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Bacterial Infection
- Urinary Tract Infection
- Sexually Transmitted Infection
- Sinus Infection
- Surgical Prophylaxis
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Injection
- Company Profiles
- Merck & Co. Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline plc.
- Pfizer Inc.
- Allergan plc.
- Abbott Laboratories
- Basilea Pharmaceutica Ltd.
- Sanofi S.A.
- F. Hoffmann-La Roche AG
- Lupin Limited
- Teva Pharmaceutical Industries Ltd.
- B. Braun Melsungen AG
- Merck & Co. Inc.*
"*" marked represents similar segmentation in other categories in the respective section.
Product Code: CMI2893
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Type
- Market Snippet, By Formulation
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Major Brand Analysis
- Reimbursement Scenario
- Epidemiology Analysis
- Porter's Five Forces Model
- Pipeline Analysis
- Switch Analysis
- Site Chain Analysis
4. Global Cephalosporin Drugs Market
- Antibiotic Resistance Trends By Country
5. Global Cephalosporin Drugs Market, By Generation, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- First-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Second-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Third-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Fourth-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Fifth-generation Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Cephalosporin Drugs Market, By Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Branded Cephalosporin Drugs
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Generic Cephalosporin Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
7. Global Cephalosporin Drugs Market, By Formulation, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Oral
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Tablets
- Capsules
- Liquid
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
8. Global Cephalosporin Drugs Market, By Indication, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Respiratory Tract Infection
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Skin Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Ear Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Bacterial Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Urinary Tract Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Sexually Transmitted Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Sinus Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Surgical Prophylaxis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
9. Global Cephalosporin Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
10. Global Cephalosporin Drugs Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Generation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Formulation, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
11. Competitive Landscape
- Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Allergan plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Lupin Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- B. Braun Melsungen AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
12. Section
- References
- Research Methodology
- About Us and Sales Contact
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.